-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $137

Benzinga·05/06/2026 15:54:42
Listen to the news
RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $136 to $137.